Valneva SE (VALN.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov26

Valneva SE Announces Positive Results for Lyme Disease Vaccine Candidate Phase 2 Trial

06:00

Nov21

Valneva SE released FY2025 9 Months Earnings on November 20 (EST), actual revenue USD 144.35 M, actual EPS USD -0.8674

04:00

Valneva SE released FY2025 Q3 earnings on November 20 (EST), actual revenue USD 34.49 M (forecast USD 45.85 M), actual EPS USD -0.5746 (forecast USD -0.2925)

04:00

Nov12

Valneva SE to Release FY2025 9 Months Earnings on November 19 (EST), Forecast Revenue USD 45.42 M, EPS USD -0.2925

00:09

Nov4

Valneva SE's Second Generation Zika Vaccine VLA1601 Shows Positive Phase 1 Clinical Trial Results

06:00

Oct9

Analyst Telliez Covers Healthcare Industry with Focus on Three Stocks

01:41

Schedules & Filings

Schedules

Filings

Nov20

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 34.49 M, Net Income -52.02 M, EPS -0.5746

Aug12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 56.57 M, Net Income -13.56 M, EPS -0.1629

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 53.29 M, Net Income -9.994 M, EPS -0.1298

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change